Ireland Natalizumab (TYSABRI) Observational Program
NCT01943526
·
clinicaltrials.gov ↗
COMPLETED
Status
191
Enrollment
INDUSTRY
Sponsor class
Conditions
Relapsing-Remitting Multiple Sclerosis
Interventions
BIOLOGICAL:
natalizumab
Sponsor
Biogen